Retatrutide and Bowel Habits: Trial Evidence

Retatrutide is an investigational triple-receptor agonist developed by Eli Lilly that acts on the GLP-1, GIP, and glucagon receptors. Questions about whether retatrutide makes you poop more reflect a broader interest in how this class of medicine affects digestion. Clinical trial data indicate that gastrointestinal effects, including changes in bowel habit, are among the most commonly reported adverse events. This article explains what the trial evidence shows, why GLP-1-based medicines alter digestion, and why retatrutide remains available only within authorised clinical trials in the UK.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an investigational triple-receptor agonist with no UK marketing authorisation; it is available only to participants in authorised clinical trials and cannot be prescribed or dispensed outside that setting.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it is available only to participants enrolled in authorised clinical trials, where supply occurs under the study protocol via the research pharmacy and trial team.^[1] There is no route by which a GP, online clinic, or pharmacy can prescribe or dispense it outside that setting.

Retatrutide is an investigational medicine developed by Eli Lilly that acts on three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[2][3] This triple-receptor mechanism distinguishes it from currently authorised medicines such as semaglutide and tirzepatide. In the UK, semaglutide is authorised as Ozempic for type 2 diabetes and as Wegovy for weight management; tirzepatide is authorised as Mounjaro for both type 2 diabetes and weight management.^[5][6] No head-to-head trials between retatrutide and these medicines have been conducted, and no direct comparisons can be drawn.

Because retatrutide is not authorised, it cannot be advertised, and no UK launch date or timeline can be given. The MHRA has not issued a marketing authorisation, and no Integrated Care Board (ICB) commissioning decision applies to it. Anyone who encounters retatrutide offered for sale online outside of a formal clinical trial should be aware that such a product would not be a licensed medicine and could be falsified or unsafe.

For people interested in weight management or type 2 diabetes treatment, licensed options do exist and can be discussed with a GP. Eligibility for retatrutide clinical studies is determined by the trial teams, not by pharmacies or online clinics.

What gastrointestinal side effects did clinical trials report?

Phase 2 trial data identified nausea, vomiting, diarrhoea, and constipation as the most common gastrointestinal adverse effects, predominantly mild to moderate and most pronounced during dose escalation.

Clinical trial data for retatrutide indicate that gastrointestinal side effects, including changes in bowel habit, were among the most commonly reported adverse events. Published findings from the Phase 2 trial reported in the New England Journal of Medicine (Jastreboff et al., 2023) identified nausea, vomiting, diarrhoea, and constipation as frequent adverse effects, particularly during dose escalation. In that trial, these effects were described as predominantly mild to moderate in severity and most pronounced in the early weeks of treatment or following a dose increase.

Phase 3 data from the TRIUMPH programme are being presented at major congresses (including ADA and EASD) as they become available; at the time of writing, full peer-reviewed publications from those studies have not yet been published, so the Phase 2 findings remain the primary source for the gastrointestinal tolerability profile described here.^[11]

Changes in stool frequency and consistency, including both looser stools and, in some participants, constipation, were reported across dose groups. These effects were consistent with the gastrointestinal profile seen with other medicines in the GLP-1 receptor agonist class.

These findings come from controlled trial populations under close medical supervision, and the safety profile in broader, real-world use has not been established. Any individual experiencing gastrointestinal symptoms within a clinical trial should report them to the trial team under the study protocol; any symptomatic treatments such as antiemetics or antidiarrhoeals should also be discussed with the trial team before use. Suspected side effects of a medicine taken outside a trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Seek urgent medical advice if you experience severe or persistent abdominal pain (which may indicate pancreatitis), persistent vomiting leading to dehydration, black or bloody stools, or severe abdominal distension. Within a trial, contact the trial team first; for urgent symptoms, call NHS 111 or, in an emergency, 999.

Why do GLP-1 based medicines affect digestion?

GLP-1 receptor activation slows gastric emptying, altering gut motility and causing changes in bowel habit, nausea, and altered stool consistency across the entire GLP-1 receptor agonist class.

GLP-1 receptor agonists affect digestion primarily because GLP-1 is a naturally occurring gut hormone that plays a direct role in regulating gastrointestinal motility. When GLP-1 receptors are activated, gastric emptying slows, meaning food moves more gradually from the stomach into the small intestine.^[12][13] This slowing is part of the mechanism that promotes satiety and reduces appetite, but it also alters the pace and pattern of digestion throughout the gut.

Retatrutide activates the GLP-1 receptor alongside the GIP and glucagon receptors. Both GIP receptors and glucagon receptors are expressed in the gastrointestinal tract and are understood to influence gut motility and secretion, though the precise interaction of all three pathways in humans is still being characterised in ongoing research.^[12][13] The combined stimulation of these receptors may therefore produce gastrointestinal effects that reflect contributions from more than one pathway.

The practical consequence for some people is that bowel habits change, sometimes towards looser or more frequent stools, and sometimes towards constipation, depending on the individual and the stage of treatment. Nausea is particularly common because slowed gastric emptying can cause a sensation of fullness or discomfort. These effects are not unique to retatrutide and are well recognised across the GLP-1 receptor agonist class. Staying well hydrated, eating smaller meals, and avoiding high-fat or high-sugar foods can help manage mild symptoms. Any persistent or severe gastrointestinal symptoms should be discussed with the trial team or a healthcare professional promptly.

Is it safe to obtain retatrutide outside of a clinical trial?

Obtaining retatrutide outside an authorised clinical trial is not safe; it has no MHRA marketing authorisation, and any product sold through unofficial channels may be falsified, contaminated, or incorrectly dosed.

Obtaining retatrutide outside of an authorised clinical trial is not safe and is not a legitimate option in the UK. Retatrutide has no marketing authorisation from the MHRA, which means it has not completed the regulatory review process that establishes a medicine's quality, safety, and efficacy to the standard required for general use. Any product sold online or through unofficial channels and labelled as retatrutide is not a licensed medicine and may be falsified, contaminated, or incorrectly dosed.

Falsified medicines are a recognised public health risk. They may contain no active ingredient, the wrong ingredient, or harmful substances. Because retatrutide is a high-profile investigational medicine attracting significant public interest, it is a plausible target for counterfeit supply chains. The MHRA actively warns against purchasing medicines from unregistered online sources; its guidance on buying medicines online is available at gov.uk/buy-medicines-online.

In Great Britain, legitimate distance-selling pharmacies are registered with the General Pharmaceutical Council (GPhC), which maintains a public register at pharmacyregulation.org. In Northern Ireland, the Pharmaceutical Society of Northern Ireland (PSNI) holds the equivalent register at psni.org.uk. Checking these registers before using any online pharmacy is a straightforward way to verify that a service is legitimate.

Within an authorised clinical trial, participant safety is protected by ethics committee oversight, protocol-defined monitoring, and direct access to the trial medical team. Outside that setting, none of those safeguards exist. If you are interested in weight management treatments that are currently authorised in the UK, speaking with your GP is the appropriate starting point. They can discuss licensed options and refer you through the correct NHS or specialist pathway. Do not attempt to source retatrutide independently, and contact your GP if you have concerns about a product you have already obtained.

Frequently Asked Questions